Regarding the four shareholder proposals at the 108th Annual General Meeting of Shareholders to be held on March 27, 2026, the Company’s Board of Directors opposes all proposals and recommends shareholders to vote against them.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4967","jir_company_name":"Kobayashi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4967-20260210-06.pdf","jir_short_summary":"Regarding the four shareholder proposals at the 108th Annual General Meeting of Shareholders to be held on March 27, 2026, the Company's Board of Directors opposes all proposals and recommends shareholders to vote against them.","jir_summary":"### Overview of Shareholder Proposals and the Board of Directors' Opinion\nAt the 108th Annual General Meeting of Shareholders scheduled for March 27, 2026, four shareholder proposals were submitted by Oasis Japan Strategic Fund Ltd. The proposals include appointing one auditor, amending the articles of incorporation regarding the convener and chairperson of the board of directors, adding a clause for sharing monthly reports with outside directors, and adding a clause to ensure thorough quality and safety management. The Company's Board of Directors unanimously resolved to oppose all proposals and recommends shareholders to vote against them.\n\n### Details of Opposition Reasons and the Company\u2019s Response\nRegarding the auditor appointment proposal, the Company is progressing with its transition to a company with an audit and supervisory committee and judged the new auditor appointment inappropriate. The proposal to limit the board chairperson qualification to outside directors is opposed as the current system, where the executing directors serve as chairperson, is considered optimal. The addition of the monthly report sharing clause is opposed because it could impair operational flexibility. The proposal to add a clause for thorough quality and safety management is opposed as these matters should be addressed under board supervision and not specified in the articles of incorporation.","jir_financial_highlights":"Auditor Appointment Proposal: Proposal to appoint Mr. Hitoshi Kawaguchi as auditor (The Company opposes this proposal due to planned transition to a company with an audit and supervisory committee)\nArticles of Incorporation Amendment Proposal (Convener and Chairperson of the Board of Directors): Proposal to limit the chairperson of the board of directors to outside directors (The Company opposes based on maintaining the current system)\nArticles of Incorporation Amendment Proposal (Monthly Report Sharing with Outside Directors): Proposal to add a clause for sharing monthly reports with outside directors (Opposed from the perspective of securing operational flexibility)\nArticles of Incorporation Amendment Proposal (Thorough Quality and Safety Management): Proposal to add a clause for thorough quality and safety management (Opposed as it should be addressed under board supervision)","jir_category":"","jir_hashtags":"#KobayashiPharmaceuticalCoLtd, #ShareholderProposals, #CorporateGovernance, #IR","jir_key_figures":"108th Annual General Meeting of Shareholders Date: 2026-03-27\nShareholder Proposer: Oasis Japan Strategic Fund Ltd.\nDecision Date for Transition to a Company with Audit and Supervisory Committee: 2026-02-10","jir_meta_title":"Kobayashi Pharmaceutical Unanimously Opposes All Shareholder Proposals at 2026 Annual General Meeting","jir_meta_description":"At the Annual General Meeting of Shareholders on March 27, 2026, Kobayashi Pharmaceutical unanimously opposed all four proposals from Oasis Japan Strategic Fund Ltd. and recommends shareholders vote against them. Announcement also includes transition to a company with an audit and supervisory committee.","jir_og_title":"Kobayashi Pharmaceutical Announces Opposition to Four Shareholder Proposals","jir_og_description":"Ahead of the Annual General Meeting in March 2026, the Board of Directors resolved to oppose all shareholder proposals and outlined plans to strengthen the audit system.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7982,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-27082","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n